ArticleAnalytical and bioanalytical chemistry2026
A luciferase immunoprecipitation system-based ultra-sensitive assay for HIV-1 p24 IgG in serum.
Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Zinc-doped carbon dots for hypochlorite ultrasensitive determination: from aqueous monitoring to live-cells imaging.Mikrochimica acta · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The human immunodeficiency virus type 1 (HIV-1) continues to pose a major global public health burden. However, progress in curbing the HIV pandemic is slowing, with the annual number of new infections remaining persistently high globally. HIV-1 p24 antigen-specific antibodies serve as the most consistent and robust markers for early HIV-1 seroconversion. Thus, the development of ultra-sensitive p24 IgG detection methods is of clinical and epidemiological significance. In this study, an assay for the detection of HIV p24-specific IgG in serum was established using the luciferase immunomagnetic system (LIMS), with the incorporation of a humanized Gaussia luciferase (hGLuc)-p24 chimeric antigen. Under optimized conditions, the assay enables semi-automated processing of 32 clinical serum samples within 15 min, with a minimal sample volume of only 2.5 μL per test. Compared to conventional enzyme-linked immunosorbent assay (ELISA), the HIV-1 p24 LIMS assay not only streamlines the experimental workflow but also exhibits superior sensitivity, a wider dynamic range for signal detection, and enhanced discrimination between positive and negative specimens. These integrated advantages render the assay particularly valuable for scenarios demanding rapid, accurate and high-throughput diagnostic responses to HIV-1 infection.
Indexed as
Identifiers
42690405What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.